By Chris Wack
Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded data from an ongoing Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
The biopharmaceutical company said the panel, consisting of experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the trial.
The panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation regarding the trial. The decision to assemble the outside panel was taken as the company hasn't been able, through review of blinded data, to determine the rationale for the DSMB's recommendation to pause enrollment and dosing in the trial.
Pliant expects this process to conclude in two to four weeks.
Following the DSMB's previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the clinical trial. Pliant said it will continue to remain blinded in order to ensure data integrity of the clinical trial with the goal of maintaining its potential to serve as a registrational trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 13, 2025 10:27 ET (15:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.